Study Results from Assam University Broaden Understanding of Alzheimer Disease (Tea Polyphenols As Multi-target Therapeutics for Alzheimer’s Disease: an In Silico Study)
Daily India Report
2019 MAY 09 (NewsRx) -- By a News Reporter-Staff News Editor at Daily India Report -- A new study on Neurodegenerative Diseases and Conditions - Alzheimer Disease is now available. According to news reporting originating in Silchar, India, by NewsRx journalists, research stated, “Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease characterized by cognitive decline, dementia, and in later stages complete loss of feelings, sensation and death. The global prevalence of the disease is on the rise, and it affects 35-40% of the population above 80 years.”
The news reporters obtained a quote from the research from Assam University, “The pathological hallmarks of the disease include extra-neuronal deposition of amyloid-beta (A beta) as plaques and intra-neuronal hyperphosphorylated tau protein as neurofibrillary tangles, which cause neurodegeneration and cerebral atrophy. A beta deposition is catalyzed by beta-secretase and gamma-secretase, while tau hyperphosphorylation is catalyzed by glycogen synthase kinase -3 beta (GSK-3 beta). With neurodegeneration, the level of the neurotransmitter acetylcholine (ACh), as well as acetylcholinesterase (AChE), decreases in the synaptic cleft, called cholinergic deficiency. This leads to the cardinal behavioural abnormalities of AD, which is referred to as cholinergic hypothesis of AD. The other enzyme which degrades ACh is the butyrylcholinesterase (BuChE). Thus, current treatment options of AD include symptomatic treatment to elevate the levels of ACh by inhibiting AChE. However, the currently used drugs cause several side effects, and the quest for novel drugs remains an interesting and essential venture. Since the disease has multiple pathophysiologies, there is an unrelenting need to develop novel drugs and lead molecules capable of inhibiting multiple pathways. The present study hypothesizes use of tea polyphenols against the key drug targets of AD, viz. beta-Secretase, gamma-Secretase, GSK-3 beta, AChE and BuChE. The hypothesis has been validated using molecular docking tools. The result indicates that the polyphenols may potentially inhibit these enzymes, similar to their known inhibitors.”
According to the news reporters, the research concluded: “Thus, the findings are of immense significance in the therapeutic interventions of AD, using tea polyphenols as exciting multi-target drugs.”
For more information on this research see: Tea Polyphenols As Multi-target Therapeutics for Alzheimer’s Disease: an In Silico Study. Medical Hypotheses, 2019;125():94-99. Medical Hypotheses can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Medical Hypotheses - http://www.journals.elsevier.com/medical-hypotheses/)
Our news correspondents report that additional information may be obtained by contacting M.K. Mazumder, Assam University, Cent Instrumentat Lab, Silchar 788011, Assam, India.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.mehy.2019.02.035. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)